A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
复制标题
DOI：
10.1586/1744666x.2016.1134319
复制
发表时间：
2016-03-03
影响因子：
4.4
通讯作者：
Saraceno, Rosita
中科院分区：
文献类型：
--
作者：
Chiricozzi, Andrea;Caposiena, Dante;Saraceno, Rosita
牛皮癣是一种常见的慢性炎症性皮肤病。作为一种终身疾病，需要对疾病进行长期和安全的控制。目前的抗银肩病治疗在耐受性和给药途径方面显示出一些限制。最近，一种新的口服小分子，阿普斯特，已被批准用于治疗中度至重度斑块型银屑病患者。阿普斯特是一种磷酸二酯酶4（PDE4）抑制剂，可调节细胞内信号的转导，包括促炎和抗炎途径。由于良好的安全性和口服给药途径，阿普斯特可能是中重度银屑病有希望的治疗靶点。在这篇综述中，我们报告了关于阿普斯特治疗银屑病的临床试验的最新概述，并试图提供有关这种抗银屑病药物的全面信息和银屑病治疗算法的未来前景。
Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show some limits in terms of tolerability and route of administration. Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways. Because of the favorable safety profile and the oral route of administration, apremilast may represent a promising therapeutic target for moderate-to-severe psoriasis. In this review, we report an updated overview about clinical trials testing apremilast in the treatment of psoriasis and seek to provide comprehensive information about this anti-psoriatic drug and a future perspective of the therapeutic algorithm for psoriasis.